Young Patients with Non-Germinal B-cell-Like Lymphoma Benefit from Dose-Intensive R-ACVBP vs. R-CHOP
the Cancer Therapy Advisor take:
According to new findings published in the Journal of Clinical Oncology, researchers have found that the Hans algorithm may be useful as a theragnostic biomarker for identifying young patients with non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL) who may benefit from dose-intensive rituximab, doxorubicin, cyclophophamide, vindesine, bleomycin, and prednisone (R-ACVBP) rather than being treated with standard rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R-CHOP).
For the analysis of data from the phase 3 trial LNH 03-2B, researchers sought to identify whether any biomarkers could predict which patients with DLBCL would experience a survival advantage when treated with dose-intensive R-ACVBP compared with R-CHOP. Researchers analyzed the interaction effects between various biomarkers and each treatment arm of the LNH 03-2B study on survival.
They used the Hans algorithm to classify tumors as GCB or non-GCB. They found that only the interaction between the Hans algorithm and the treatment arm was significantly associated with progression-free survival and overall survival (P = 0.01).
Progression-free survival and overall survival were similar between both regimens among patients with GCB tumors, but patients with non-GCB tumors had better outcomes when treated with dose-intensive R-ACVBP compared with R-CHOP.
DLBCL may benefit from dose-intensive R-ACVBP.
This study aims to determine whether any tumor biomarkers could account for the survival advantage observed in the LNH 03–2B trial among patients with diffuse large B–cell lymphoma (DLBCL) and low–intermediate risk according to the International Prognostic Index when treated with dose–intensive rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R–ACVBP) compared with standard rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R–CHOP).
The survival benefit related to R–ACVBP over R–CHOP is at least partly linked to improved survival among patients with non–GCB DLBCL.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma